Beacon Biosignals: AI-Enabled Neurotechnology for Clinical Trials and Sleep Testing

Overview: How Beacon’s AI-Driven Neurotechnology Platform Supports Clinical Research and Sleep Diagnostics

Beacon is an AI-enabled neurotechnology platform that collects, integrates and analyses EEG and related physiological data to support clinical research, drug development and home sleep testing. It addresses the difficulty of measuring brain function consistently beyond specialist testing environments, combining at-home data collection with centralised analysis. Its research offering spans clinical trial design, neurophysiological assessment and biomarker discovery, while its sleep-testing services extend measurement into everyday settings.

The platform applies AI-driven analysis to neurophysiological and cardiopulmonary recordings, turning complex signals into quantitative information for research and assessment. EEG captures electrical brain activity, providing a basis for examining sleep and brain-function patterns. Beacon combines these measurements with data integration and analytical services across the drug-development lifecycle, supporting investigation of treatment effects and potential biomarkers rather than establishing therapeutic benefit on its own.

Two practical benefits are multi-night measurement in a person’s natural sleep environment and a connected workflow for collecting and analysing physiological data. Repeated home measurements can provide a broader view of sleep than a single testing occasion, while integrated analysis supports interpretation across research datasets. These capabilities may inform trial planning and clinical assessment; faster development timelines or improved outcomes remain application-specific benefits to demonstrate.

Last checked on 16 October 2026: Beacon Biosignals’ live site presents a unified clinical-research and home sleep-testing portfolio, with recent announcements covering expanded pharmaceutical collaborations and an approximately $97 million Series B financing round.

What is Beacon?

Beacon Biosignals is an AI-enabled neurotechnology provider that collects, integrates and analyses EEG and related physiological data for clinical trials, biomarker discovery and home sleep testing. It serves pharmaceutical and biotechnology research teams, clinical researchers and healthcare providers, including sleep physicians and neurologists. Its approach combines at-home physiological recording with AI-driven analysis and data services, supporting both drug-development research and sleep-assessment workflows.

Intended Use and Limitations

• Waveband, formerly Dreem 3S, has FDA 510(k) clearance under K223539; this is device-specific clearance, not blanket approval of Beacon’s platform or biomarkers.

• Beacon announced FDA 510(k) clearance for SleepStageML in March 2024, covering automated sleep staging from clinical polysomnography EEG recordings to support sleep-disorder assessment.

• Takeda expanded its strategic collaboration with Beacon in November 2025 to investigate narcolepsy diagnostic pathways and sleep neurobiomarkers using at-home EEG and AI analysis.

• Harmony Biosciences partnered with Beacon to incorporate quantitative EEG into two Phase 3 HBS-301 studies in narcolepsy and idiopathic hypersomnia.

• Beacon acquired Dreem’s hardware and software assets in 2023, bringing wearable sleep-monitoring technology into its clinical-trial offering.

• Beacon acquired CleveMed in April 2025, adding home sleep-testing technology and services; the businesses are being integrated under the Beacon name.

• An April 2026 Series B extension brought the round to approximately $97 million and cumulative funding above $132 million; financing supports corporate continuity but does not establish clinical effectiveness.

• AMIE-independent privacy claims aside, Beacon-specific HIPAA/GDPR commitments, ISO certifications and SOC 2 attestation were not established by the official materials reviewed; buyers should request current documentation rather than infer compliance from FDA clearance.